Daniel D. Mikol, MD, PhD (he/him/his)

Chief Medical Officer
NervGen Pharma Corp
Simi Valley, California, United States

Dr. Mikol received a B.S. in Chemistry from Loyola University of Chicago and was awarded a Fulbright Scholarship to study immunology at Ludwig-Maximilians-Universität München, Germany. He obtained his M.D. and Ph.D. and completed his internship at the University of Chicago Pritzker School of Medicine. His Ph.D. work in Molecular Biology/Pathology were carried out in the laboratory of Dr. Kári Stefánsson. Dr. Mikol completed his Neurology residency at the University of California, San Francisco, and fellowship in the Department of Neurology at the University of Michigan, before joining the University of Michigan as faculty. In 2008, Dr. Mikol left academics to pursue an industry career. He has held positions in neuroscience clinical development at EMD Serono, Novartis, Biogen and Amgen, prior to joining NervGen as Chief Medical Officer in 2021 to lead the development of NVG-291 in spinal cord injury.

Presentation(s):

• NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with Spinal Cord Injury

  Tuesday, October 31, 2023
  4:00 PM – 4:15 PM